ProShare Advisors
CADL icon

ProShare Advisors’s Candel Therapeutics CADL Stock Holding History

ProShare Advisors’s Portfolio CADL Stock Details CADL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-10,433
Closed -$58.9K – 1890
2025
Q4 		$58.9K Buy
+10,433
New +$56.1K ﹤0.01% 1939

Other funds holding CADL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

ProShare Advisors's CADL Position: Q1 2026 in Review

ProShare Advisors sold out of Candel Therapeutics (CADL) in Q1 2026, closing a stake of 10,433 shares — an estimated $58.9K sold.

ProShare Advisors first reported a position in CADL in Q4 2025 and held it in 1 quarter. The position peaked at $58.9K in Q4 2025. 114 funds tracked by Wall St. Rank hold CADL as of Q1 2026.

  • ProShare Advisors reported no remaining Candel Therapeutics position as of Q1 2026 after selling out during the quarter.
  • ProShare Advisors sold 10,433 Candel Therapeutics shares in Q1 2026, an estimated $58.9K.
  • ProShare Advisors first reported a position in Candel Therapeutics in Q4 2025 and held it in 1 quarter.
  • ProShare Advisors's Candel Therapeutics position peaked at $58.9K in Q4 2025.
  • 114 funds tracked by Wall St. Rank held Candel Therapeutics as of Q1 2026.

Based on ProShare Advisors's 13F filing for Q1 2026, filed 27 Apr 2026.